🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

3,067 results for “Hospital” Clear

  1. Venetoclax

    The First People's Hospital of Lianyungang

    Precursor B-Cell Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  2. Venetoclax

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    FLT3 Gene Mutation

    phase 2 small molecule active

    1 trial

  3. Venetoclax, Azacitidine

    The First People's Hospital of Lianyungang

    T-cell Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  4. Venetoclax, Azacitidine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Myeloid Leukemia

    phase 2 small molecule terminated

    1 trial

  5. Venetoclax；Azacitidine；Homoharringtonine

    The First People's Hospital of Lianyungang

    Secondary Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  6. Verzenios 50 mg film-coated tablets

    Ningbo Cancer Hospital

    High/intermediate risk hormone receptor (HR) positive/human epidermal growth factor receptor 2 (HER2) negative breast cancer patients with indication of neoadjuvant therapy.

    phase 2 small molecule active

    1 trial

  7. Vibecotecotamab combined with Putilimab for EGFR-positive refractory biliary malignant tumors

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cancer of Biliary Duct

    phase 2 small molecule active

    1 trial

  8. Vincristine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Precursor Cell Lymphoblastic Leukemia-Lymphoma

    phase 2 small molecule active

    1 trial

  9. WJMSCs Vs. placebo

    The First People's Hospital of Lianyungang

    Ischemic Cardiomyopathy

    phase 2 mab active

    1 trial

  10. Wei Li Bai capsules

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Alzheimer Disease

    phase 2 small molecule terminated

    1 trial

  11. XELOX combined with Fruquintinib and Sintilimab

    The First People's Hospital of Lianyungang

    Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  12. YPEG-rhEPO

    The First People's Hospital of Lianyungang

    Renal Anemia of Chronic Kidney Disease

    phase 2 small molecule completed

    1 trial

  13. Yi Qi Yang Yin Decoction

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Primary Sjögren Syndrome

    phase 2 small molecule active

    1 trial

  14. Yigansan

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Tourette Disorder

    phase 2 small molecule completed

    1 trial

  15. Yondelis 1 mg powder for concentrate for solution for infusion, DOXORUBICINE ARROW 2 mg/ml, solution pour perfusion

    Ningbo Cancer Hospital

    Localized, resected, FIGO stage I (2018 classification), uterine leiomyosarcoma

    phase 2 small molecule active

    1 trial

  16. Yougui granules

    The First People's Hospital of Lianyungang

    Renal Insufficiency, Chronic

    phase 2 small molecule terminated

    1 trial

  17. Zanubrutinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  18. Zanubrutinib

    The First People's Hospital of Lianyungang

    Non Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  19. Zanubrutinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Immune Thrombocytopenia

    phase 2 small molecule active

    1 trial

  20. Zanubrutinib

    The First People's Hospital of Lianyungang

    Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  21. Zanubrutinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Refractory/Relapsed Autoimmune Hemolytic Anemia

    phase 2 small molecule active

    1 trial

  22. Zanubrutinib+Rituximab+Lenalidomide

    The First People's Hospital of Lianyungang

    Diffuse Large B Cell Lymphoma

    phase 2 small molecule active

    1 trial

  23. Zanubrutinib, Fludarabine, cyclophosphamide and rituximab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  24. Zaunbrutinib, Bendamustine and Rituximab for induction therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Waldenström Macroglobulinemia (WM)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources